Clinical Trial Update: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of a Thorium-227 labeled antibody-chelator conjugate alone and in combi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)
• Thorium-227 labeled antibody-chelator conjugate

Snippet

Sponsor: Bayer | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Status: COMPLETED